Table III.
Therapy and inflammatory status of the mGPS low and high patient groups.
| mGPS low | mGPS high | ||||
|---|---|---|---|---|---|
| Variables | n=21 | (%) | n=11 | (%) | P-value |
| ECOG PS | 0.038a | ||||
| 0 | 12 | 57 | 3 | 27 | |
| 1 | 9 | 43 | 4 | 36 | |
| 2 | 0 | 0 | 2 | 18 | |
| 3 | 0 | 0 | 1 | 9 | |
| 4 | 0 | 0 | 1 | 9 | |
| MSKCC | 0.018b | ||||
| Favorable | 1 | 4 | 0 | 0 | |
| Intermediate | 18 | 86 | 5 | 45 | |
| Poor | 2 | 10 | 6 | 55 | |
| Histology | 0.018b | ||||
| CC | 18 | 86 | 5 | 45 | |
| pRCC | 0 | 0 | 3 | 27 | |
| Others | 3 | 14 | 3 | 27 | |
| Therapeutic drugs | 0.0647b | ||||
| Sunitinib | 12 | 57 | 6 | 54 | |
| Sorefenib | 3 | 14 | 1 | 5 | |
| Pazopanib | 5 | 24 | 2 | 10 | |
| Temsirolimus | 1 | 5 | 2 | 10 | |
| Subsequent therapyc | 0.003b | ||||
| None | 1 | 5 | 7 | 64 | |
| Second-line | 15 | 72 | 4 | 36 | |
| Third or further-line | 7 | 33 | 2 | 18 | |
Wilcoxon rank sum test
Pearson's Chi-square test
None, number of patients, who completed first-line chemotherapy alone, or who are currently receiving first-line therapy; second-line, number of patients who received second-line chemotherapy, or who are currently treated with second-line chemotherapy; third- or further-line, number of patients, who received third- or further-line chemotherapy, or who are currently treated with third- or further-line chemotherapy. Based on the definition of each item, 2 patients are repeatedly counted in both the mGPS low and the mGPS high groups. mGPS, modified Glasgow Prognostic Score; ECOG PS, Eastern Cooperative Oncology Group performance status; MSKCC, Memorial Sloan Kettering Cancer Center; CC, clear cell; pRCC, papillary renal cell carcinoma.